Mucosal Healing and Clinical Remission in Inflammatory Bowel Diseases

2013 ◽  
Vol 19 (4) ◽  
pp. E55-E56 ◽  
Author(s):  
Dario Sorrentino
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Clinical Remission ◽  
Mucosal Healing ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing

Immunotherapy ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 565-575
Author(s):  
Ferdinando D’Amico ◽  
Gionata Fiorino ◽  
Laurent Peyrin-Biroulet ◽  
Silvio Danese
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Mucosal Healing ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Symptomatic Control

scholarly journals Resolution of Inflammation and Gut Repair in IBD: Translational Steps Towards Complete Mucosal Healing

2020 ◽  
Vol 26 (8) ◽  
pp. 1131-1143 ◽  
Author(s):  
Gwo-tzer Ho ◽  
Jennifer A Cartwright ◽  
Emily J Thompson ◽  
Calum C Bain ◽  
Adriano G Rossi
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Inflammatory Cell ◽  
Mucosal Healing ◽  
Treatment Target ◽  
Resolution Of Inflammation ◽  
Epithelial Repair ◽  
New Knowledge ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Macrophage Populations

Abstract Despite significant recent therapeutic advances, complete mucosal healing remains a difficult treatment target for many patients with inflammatory bowel diseases (IBD) to achieve. Our review focuses on the translational concept of promoting resolution of inflammation and repair as a necessary adjunctive step to reach this goal. We explore the roles of inflammatory cell apoptosis and efferocytosis to promote resolution, the new knowledge of gut monocyte-macrophage populations and their secreted prorepair mediators, and the processes of gut epithelial repair and regeneration to bridge this gap. We discuss the need and rationale for this vision and the tangible steps toward integrating proresolution therapies in IBD.

scholarly journals P360 Safety and clinical efficacy of double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicentre study

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S342-S342
Author(s):  
S Mazza ◽  
A Fascì ◽  
V Casini ◽  
C Ricci ◽  
F Munari ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Inflammatory Bowel Diseases ◽  
Clinical Remission ◽  
Comparable Efficacy ◽  
Potential Cost ◽  
Safety And Efficacy ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Double Switch

Abstract Background Since infliximab (IFX) patent expiry in 2015, several IFX biosimilars have been licensed in EU for all indications, including inflammatory bowel diseases (IBD). IFX biosimilars currently available in Italy include CT-P13 and SB2, both of which demonstrated comparable efficacy, safety and immunogenicity with IFX originator in IBD patients. Safety and clinical efficacy of single switch from originator IFX to CT-P13 have also been confirmed in a prospective clinical trial. On the contrary, data regarding multiple therapeutic switching of IFX originator with CT-P13 and SB2 are currently lacking. Methods This study was aimed to evaluate the safety and efficacy of double switch from IFX originator to CT-P13 and subsequently to SB2 in patients with IBD. From November 2018 to May 2019, patients undergoing IFX double switch in 8 Centres in Lombardy were retrospectively analysed. The overall rate of IFX discontinuation, incidence and type of adverse events (AE) and proportion of patients on clinical remission over time were recorded. Data were compared with a control group of 66 IBD patients single switched from IFX originator to CT-P13. Results Fifty-two double-switched IBD patients were enrolled (63% M, mean age 41 years, 75% Crohn’s disease, 25% ulcerative colitis). Main indications for IFX therapy were moderate to severe disease (50%) and steroid-dependent disease (25%). The overall 24- and 48-week IFX discontinuation rates following second switch (CTP13->SB2) were 2% (95% CI 0–6%) and 14% (95% CI 3–25%), respectively. During a median follow-up of 40 weeks (18–48), 4 patients (12%) experienced a total of 6 AE (2 cutaneous, 2 infectious, 1 articular and 1 immunological), leading to IFX discontinuation in 3 cases (6%). No infusion reactions were observed. At week 24 following second switch, 49 (94%) patients were in clinical remission, the remaining 3 patients not being in remission already at the time of second switch. Only one patient lost response after week 24, 48 (92%) of patients being in clinical remission at the end of follow-up. No differences in IFX discontinuation, AE and clinical remission rates were found between double-switched and single-switched patients. No clinical parameters were found to predict safety and efficacy outcomes. Conclusion The study supports both safety and efficacy of the double switch from IFX originator to CT-P13 and SB2 in patients with IBD, and demonstrates its non-inferiority to a single switch strategy, with potential cost implications.

Mucosal Healing in Inflammatory Bowel Diseases

2015 ◽  
Vol 21 (1) ◽  
pp. 198-207 ◽  
Author(s):  
Annaïg Lan ◽  
François Blachier ◽  
Robert Benamouzig ◽  
Martin Beaumont ◽  
Christophe Barrat ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Mucosal Healing ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Noninvasive evaluation of mucosal healing in inflammatory bowel diseases

2012 ◽  
Vol 6 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Jun Kato ◽  
Sakiko Hiraoka ◽  
Asuka Nakarai ◽  
Masao Ichinose
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Mucosal Healing ◽  
Noninvasive Evaluation ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Histological Hallmarks of Mucosal Healing in Inflammatory Bowel Diseases in the Era of Monoclonal Antibodies Therapy: New Insights and Perspectives

Diagnostics ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 1570
Author(s):  
Gerardo Cazzato ◽  
Anna Colagrande ◽  
Valeria Andriola ◽  
Teresa Lettini ◽  
Sebastiano Cicco ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Natural History ◽  
Inflammatory Bowel Diseases ◽  
Careful Analysis ◽  
Mucosal Healing ◽  
Level Of Evidence ◽  
Clinical Endpoints ◽  
Bowel Diseases ◽  
History Of ◽  
Inflammatory Bowel

Background: Chronic inflammatory bowel diseases (IBDs) are gaining increasing attention, both because they can severely reduce the quantity and quality of life, and because the advent of monoclonal antibodies has profoundly changed the natural history of these diseases. In recent years, the concept of mucosal healing has assumed a certain importance, and there are more and more clinical and pharmacological trials that consider this parameter among their endpoints, so much so that it may soon be included among the desirable clinical outcomes of patients with IBD. Methods: We performed a literature review of the Pubmed, Medline, and Web of Science (WoS) databases. Results: We selected 88 articles and then removed 6 duplicates; the final sample after accurate application of the inclusion criteria numbered 73 articles, with a level of evidence rating of three or four, according to Oxfords Evidence-based medicine. Our aim was to study the histological impact of monoclonal antibody therapies on mucosal healing, taking into consideration the few studies present in the literature. To perform this review, we compared studies that examined patients with Crohn’s disease (CD) and/or ulcerative colitis (UC) undergoing monoclonal therapy versus patients undergoing other non-biological therapies (PICO statements). Conclusions: We try to delineate how monoclonal antibodies have changed the natural history of IBD, acting at the microscopic level, and we believe that a careful analysis of the histopathology and the definition of the objective criteria for “Mucosa Healing” should enable this concept to be included among the clinical endpoints of patients affected by IBD, thus contributing to a better therapeutic management of these patients.

Sign in / Sign up

Export Citation Format

Share Document